Affymax Unveils Peptide EPO Mimic

18 August 1996

Researchers at Glaxo Wellcome subsidiary Affymax have developed a small peptide which can mimic the effects of erythropoietin. It is the first time that a small peptide has been designed which can duplicate the effects of a large polypeptide hormone, according to a report in Science (July 25).

Interestingly, the structure of the peptide has no sequence or structural homology with EPO, but nevertheless seems to behave as a full agonist. The peptide was developed using Affymax' proprietary phage display screening technology, in which billions of oligonucleotide sequences are inserted into the genes coding for the coat of a filamentous phage. The peptides coded by the oligonucleotides are displayed on the surface of the phages, for screening against a target molecule.

Recombinant EPO products, which are currently administered intravenously for a variety of indications including anemia caused by chemotherapy and kidney disease, generates over $2.5 billion in sales every year, so a small molecule mimetic could have significant revenue potential.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight